Daniel Tanner

As a Senior Vice President at Parexel Biotech, Dan leads the EMEA commercial organization, which provides tailored and innovative solutions to emerging and mid-sized biotech companies that enable them to de-risk clinical development and accelerate life-saving therapies.

As an experienced drug development leader, he works closely with executive teams, venture capital, and boards to create impactful partnerships with Parexel that leverage the full spectrum of capabilities and therapeutic expertise to deliver value-added, customer-centric solutions that improve patients’ lives.

Experience
Dan has spent over two decades in drug development and sales leadership across major international service providers, including Syneos Health and ICON, as well as technology (Clario) and most recently central and specialty labs (Cerba Research), giving him a unique, holistic perspective on the market.

Education
Dan holds a BSc in Biochemistry from the University of Warwick and an Executive MBA from Imperial College Business School.